GTG.AX - Genetic Technologies Limited

ASX - ASX Delayed price. Currency in AUD
0.009
+0.001 (+12.50%)
At close: 3:32PM AEST
Stock chart is not supported by your current browser
Previous close0.008
Open0.009
Bid0.008 x 0
Ask0.010 x 0
Day's range0.009 - 0.010
52-week range0.006 - 0.021
Volume4,216,437
Avg. volume5,082,862
Market cap21.918M
Beta2.45
PE ratio (TTM)N/A
EPS (TTM)-0.003
Earnings date1 Mar. 2016 - 5 Mar. 2016
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • GlobeNewswire4 hours ago

    Genetic Technologies Announces Heads of Agreement with Swisstec

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a Heads of Agreement with Swisstec Health Analytics Ltd. (“Swisstec”) to work together over the next 30 days to finalise a Proposed Joint Venture (PJV) to establish a new Company, (“JV Company”). The JV Company will enable both companies to collaborate to develop a service platform using blockchain technology that will provide a marketplace for medical services and personalised health management, and will also facilitate data management and AI-based services to promote better patient outcomes.

  • GlobeNewswire12 days ago

    Genetic Technologies Announces Binding Project Shivom Agreement

    Project Shivom to provide GTG access to a significant pool of data, particularly related to the Indian population. GTG, through access to the Indian population data to modify its risk assessment kits as well as to develop new Indian specific tests or products, including tests related to diabetes and other disease, based on opportunity and areas of need.

  • GlobeNewswire2 months ago

    Genetic Technologies Announces Grant from NHMRC Awarded to University of Melbourne to Substantially Improve Breast Cancer Risk Prediction and Increase Accessibility 

    Genetic Technologies Limited (ASX:GTG) (GENE) (“Company”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce the award of an NHMRC Partnership Grant to a research team led by Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population & Global Health at The University of Melbourne.